UNSPSC 51151637: Elantrine

This classification denotes an anticholinergic agent with the molecular formula C20H24N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MV4FO7V23V, chemically known as rmi 80,029 but generally known as elantrine, which bears US NIH Compound Identifier 5383521. European Medicines Agency schedules Elantrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06476MIG. The term ELANTRINE is an International Non-Proprietary Name.

UNSPSC 51151637 Elantrine, a Commodity code, covers pharmaceutical products and related health-system supplies that state and local governments procure for public health and community health initiatives. Recent solicitations show state and local agencies buying naloxone and drug deactivation systems for emergency response and harm-reduction programs, as well as exploring direct-to-manufacturer prescription fulfillment models to optimize pharmacy benefit management and cost control. The issuing bodies include county health departments and state health and human services agencies. Scope spans the procurement of finished pharmaceutical products (such as overdose-reversal medications), drug deactivation and disposal systems, and the establishment of alternative supply-chain relationships that bypass traditional pharmacy benefit managers and wholesalers.

Recent activity appears concentrated in Florida and Texas. Seminole County, Florida issued an IFB in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county's community health building; the IFB, posted June 30, 2026, closed July 26, 2023 (note: date discrepancy in source), with fixed-fee pricing and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted an RFI in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative program enabling direct contracts between state pharmacy benefit programs and manufacturers, exploring alternatives to traditional pharmacy benefit manager and group purchasing organization arrangements. The RFI, closed April 3, 2026, represents early-stage market intelligence-gathering rather than a committed procurement. No other state or local opportunities are documented in the source for this code.